Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | N581T |
| Impact List | missense |
| Protein Effect | no effect - predicted |
| Gene Variant Descriptions | BRAF N581T lies within the protein kinase domain of the Braf protein (UniProt.org). N581T has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Braf in culture (PMID: 29533785), and therefore, is predicted to have no effect on Braf protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
BRAF mutant BRAF N581X BRAF N581T |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140753393T>G |
| cDNA | c.1742A>C |
| Protein | p.N581T |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001354609.2 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| NM_004333 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| NM_001378474.1 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| NM_001354609.1 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| XM_005250045 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| NM_004333.5 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| NM_001378468.1 | chr7:g.140753393T>G | c.1742A>C | p.N581T | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF N581T | colorectal cancer | not predictive | Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Case Reports/Case Series | Actionable | In a clinical study, the combination of Vectibix (panitumumab) with FOLFOX as a first-line therapy resulted in a partial response with progression-free survival lasting 1.4 months in a patient with metastatic colorectal cancer harboring BRAF N581T (PMID: 31515458). | 31515458 |